Interested in learning from Canadian researchers at the forefront of psychedelic science? Consider this your invitation to join the Research Room, our monthly online expert-led series. Register for free today!
The MAPS Canada Research Room is a monthly webinar series dedicated to showcasing cutting-edge Canadian research across diverse disciplines within the burgeoning field of psychedelic studies. Our mission is to democratize access to psychedelic science, and fostering inclusivity through knowledge translation and dissemination of academic knowledge in a more accessible manner.
Each research room session is an hour long, and provides researchers a platform through which they can dynamically engage with the audience about their current research.
Interested in presenting or would like to see someone present? Click here for to sign up.
For more information email us at: researchroom@mapscanada.org
- Meetings are held on Zoom
- First Thursday of every month, 7 PM ET (4 PM PT) (see note)
- Anyone with an interest in psychedelic science and research, anywhere in the world, is welcome to attend.
UPCOMING SESSIONS
February 19, 2026
MAPS Canada presents:
Psychedelic-Assisted Couples Therapy: Trauma-focus and beyond
Thu, February 19th, 7pm EST / 4pm PST
PAST SESSIONS
MAPS Canada Research Room presents:
Investigating other psychedelics for mental health: AtaiBeckley pipeline update and development progress of BPL-003, VLS-01 and EMP-01 programs
Speaker Bio: Hailey is a Master’s level biostatistician with over 16 years of experience in clinical research oversight. She has contributed to the lifecycle of more than 60 clinical trials, and is a co/author on 30+ publications and talks spanning several therapeutic areas. The nexus of health, justice, and impact is the ethos for the work she chooses. After spending 11 years managing NIH-funded HIV clinical trials in the U.S., South America, and Africa, including multiple regulatory approvals of drugs and devices, Hailey came to psychedelics. Since 2020 Hailey has worked at the intersection of Clin Ops and Med Affairs for MAPS PBC/Lykos Therapeutics, as a private consultant, and for AtaiBeckley, managing programs in the US, Canada, South America, Europe, and Australia. She was an SSDP Pipeline Mentor for 3 years, and her work has been featured on Psychedelic Alpha and The Trip Report podcast. Talk Abstract – AtaiBeckley is a clinical-stage biopharmaceutical company focused on developing innovative mental health treatments, primarily utilizing psychedelic compounds. Our pipeline targets conditions with significant unmet needs like treatment-resistant depression (TRD), social anxiety disorder (SAD), and alcohol use disorder (AUD).Key candidates include BPL-003 (intranasal 5-MeO-DMT), which has shown rapid and durable antidepressant effects in Phase 2a-b studies for TRD. VLS-01 (buccal film DMT) is in Phase 2 for TRD, targeting a short in-clinic treatment time and EMP-01 (oral R-MDMA) has completed a Phase 2 study for SAD.
Talk Abstract: AtaiBeckley is a clinical-stage biopharmaceutical company focused on developing innovative mental health treatments, primarily utilizing psychedelic compounds. Our pipeline targets conditions with significant unmet needs like treatment-resistant depression (TRD), social anxiety disorder (SAD), and alcohol use disorder (AUD).Key candidates include BPL-003 (intranasal 5-MeO-DMT), which has shown rapid and durable antidepressant effects in Phase 2a-b studies for TRD. VLS-01 (buccal film DMT) is in Phase 2 for TRD, targeting a short in-clinic treatment time and EMP-01 (oral R-MDMA) has completed a Phase 2 study for SAD.
Research Room Team
Aakanksha Sahu
Team Lead
